Skip to main content
Clinical Trials/NCT05167565
NCT05167565
Completed
N/A

Prospective Study to Investigate Changes in Both Brain and Behavior and Its Underlying Neural Correlates in Human Infants

Hospices Civils de Lyon1 site in 1 country80 target enrollmentOctober 17, 2022

Overview

Phase
N/A
Intervention
MRI/DTI
Conditions
Healthy Volunteers
Sponsor
Hospices Civils de Lyon
Enrollment
80
Locations
1
Primary Endpoint
Diffusivity
Status
Completed
Last Updated
2 months ago

Overview

Brief Summary

The unique importance of human brain development during the first years of life is unquestionable. During an infant's first year, the brain undergoes its most dramatic structural and functional changes, with factors such as early social experience having a significant effect on this development. This study proposes to investigate changes in both brain and behavior across the first 12 months of life. At three time points (~3, 6, and 12 month), anatomical and diffusion magnetic resonance imaging (MRI), resting state functional magnetic resonance imaging (fMRI), electroencephalography (EEG), eye tracking, and observational data will be obtained from the same sample of infants. These measures will be used to track the development of important sensorimotor, socio-emotional, and cognitive skills and their underlying neural correlates, as well as investigate the effects of early social experience on specific aspects of this development

Registry
clinicaltrials.gov
Start Date
October 17, 2022
End Date
January 28, 2026
Last Updated
2 months ago
Study Type
Interventional
Study Design
Single Group
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Healthy newborns, boys and girls, aged 3 months
  • Uncomplicated pregnancy and delivery, APGAR scores \>8
  • Full-term birth without identified neuromotor problems at birth
  • No congenital or developmental anomalies affecting the brain
  • No reported history of neurological disorders or learning disabilities in the infants
  • No reported specific visual, developmental and cognitive impairment
  • Absence of medication having a cerebral or psychological impact
  • Both parents/ legal guardian must provide their consent and signature prior to participation of their infant in the study

Exclusion Criteria

  • Severe congenital malformation
  • Infants requiring a corrective surgery
  • Any refusal of a parent
  • Infants with severe impairment of the general condition and vital functions
  • Infants with dermatitis of the face or scalp
  • Infants who receive neurological treatment
  • Infants born pre-term (birth before 37 weeks gestation)
  • Infants whose mothers have significant medical conditions and/or had significant complications during pregnancy
  • Infants who are adopted,
  • Infants who have a first degree relative with autism, intellectual disability, schizophrenia, or bipolar disorder,

Arms & Interventions

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: MRI/DTI

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: EEG

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: Eye Tracking

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: Ages and Stages Questionnaire (ASQ)

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: Infant Behavior Questionnaire Revised (IBQ-R)

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: Beck Depression Inventory (BDI)

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: The Brief Fear of Negative Evaluation Scale (BFNE)

Infants aged around 3 month

80 infants aged around 3 months will be included in this study up to around 12.5 months

Intervention: Edinburgh Postnatal Depression Scale

Outcomes

Primary Outcomes

Diffusivity

Time Frame: 9 months following the inclusion

Integrity of white matter fiber tracts assessed by DTI measures of the mean, radial, and axial diffusivity (mm2/s) along them.

Regional myelination

Time Frame: 9 months following the inclusion

Regional myelination assessed by T1 / T2 intensity ratios.

Fractional anisotropy

Time Frame: 9 months following the inclusion

Integrity of white matter fiber tracts assessed by DTI measures of the mean fractional anisotropy (0-1, where 0=isotropic diffusion, 1=diffusion restricted along one dimension) along them.

Secondary Outcomes

  • Motor beta burst timing(9 months following the inclusion)
  • Infant Behavioral Questionnaire Revised score(9 months following the inclusion)
  • Brief Fear of Negative Evaluation total score(9 months following the inclusion)
  • Edinburgh Postnatal Depression Scale total score(9 months following the inclusion)
  • Motor beta burst peak frequency(9 months following the inclusion)
  • Infant eye movement attentional bias(9 months following the inclusion)
  • Ages and Stages Questionnaire scores(9 months following the inclusion)

Study Sites (1)

Loading locations...

Similar Trials